Roche’s Ocrevus Demonstrates Near-Complete Reduction of Relapse and Lesions in Multiple Sclerosis

1. Roche's Ocrevus, a disease-modifying therapy (DMT), has achieved a near-complete suppression of multiple sclerosis (MS) relapses and lesions.
2. The long-term efficacy and safety of Ocrevus were demonstrated in a 5-year analysis of the double-blind phase (DBP) and open-label extension (OLE) of the pooled OPERA I/II studies.
3. Patients who initiated Ocrevus earlier exhibited a lower cumulative proportion of 24-week confirmed disability progression (CDP) compared to those initially receiving interferon (IFN)-β-1a.
4. Continuing Ocrevus treatment and switching from IFN-β-1a to Ocrevus led to near-complete and sustained suppression of relapse and lesion activity.
5. Ocrevus treatment also resulted in less whole brain volume loss compared to patients switching from IFN-β-1a.
6. Adverse events were consistent with past reports, and no new safety signals emerged with prolonged treatment.
7. Ocrevus's subcutaneous formulation also demonstrated near-complete reduction of relapse and lesions in one-year data.

These findings highlight the potential of Ocrevus as a highly effective therapy for managing relapsing multiple sclerosis and its associated clinical and MRI measures of disease activity.